Advertisement
U.S. markets open in 6 hours 26 minutes
  • S&P Futures

    5,208.25
    -6.50 (-0.12%)
     
  • Dow Futures

    39,216.00
    -7.00 (-0.02%)
     
  • Nasdaq Futures

    18,185.25
    -46.25 (-0.25%)
     
  • Russell 2000 Futures

    2,047.10
    -2.70 (-0.13%)
     
  • Crude Oil

    82.51
    -0.21 (-0.25%)
     
  • Gold

    2,159.60
    -4.70 (-0.22%)
     
  • Silver

    25.11
    -0.15 (-0.61%)
     
  • EUR/USD

    1.0868
    -0.0008 (-0.08%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2706
    -0.0023 (-0.18%)
     
  • USD/JPY

    150.3240
    +1.2260 (+0.82%)
     
  • Bitcoin USD

    64,643.02
    -3,729.16 (-5.45%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A

  • Cocrystal Pharma Inc (NASDAQ: COCP) announced that CC-42344 demonstrated a favorable safety profile in the single-ascending and multiple-ascending dose portions of the ongoing Phase 1 study.

  • CC-42344 is a broad-spectrum oral antiviral for pandemic and seasonal influenza A.

  • The randomized, double-controlled, dose-escalating Phase 1 study in Australia was designed to assess the safety, tolerability, and pharmacokinetics (PK) of orally administered CC-42344 in healthy adults.

  • Related: Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate.

  • In July 2022, Cocrystal reported that PK data from the single-ascending dose portion of the study supported once-daily dosing.

  • In October 2022, enrollment in the multiple-ascending dose portion of the trial was completed.

  • The company plans to present topline study results at the upcoming World Antiviral Congress on December 1 and submit an application with the United Kingdom Medicines and Healthcare Products Regulatory Agency to conduct a Phase 2a human challenge study in early 2023.

  • Subject to regulatory agency clearance, the Phase 2a study is expected to be initiated in the second half of 2023.

  • Price Action: COCP shares are up 2.49% at $3.07 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement